Navigation Links
Beckman Coulter Announces First Quarter 2009 Results
Date:4/28/2009

n assets and liabilities, net of acquisitions Trade and other receivables 33.7 15.0 Prepaid and other current assets (1.9) 4.6 Inventories (41.6) (31.5) Accounts payable and accrued expenses 8.8 (38.6) Income taxes payable 9.7 (7.3) Long-term lease receivables 4.3 2.3 Other (0.8) 2.9 ----- --- Net cash provided by operating activities 105.7 61.6 ----- ---- Cash flows from investing activities Additions to property, plant and equipment (30.9) (17.1) Additions to customer leased instruments (29.6) (47.9) Proceeds from sales of building and land - 3.0 Payments for business acquisitions and technology license assets, net of cash acquired - (14.2) --- ------ Net cash used in investing activities (60.5) (76.2) ------ ------ Cash flows from financing activities Dividends to stockholders (10.8) (10.5) Proceeds from issuance of stock 11.1 13.8 Repurchase of common stock held in grantor trust (1.3) (0.9) Excess tax benefits from share-based payment transactions 0.6 2.3
'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
2. Beckman Coulter to Webcast Annual Stockholders Meeting
3. Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation
4. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
5. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
6. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
7. Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Beckman Coulter to Host Annual Business Review
9. Beckman Coulter to Present at Upcoming Healthcare Conferences
10. Beckman Coulter to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
11. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
... 8 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ... the peer-reviewed Journal of Immunotherapy (1) demonstrating the ... to carcinoembryonic antigen (CEA) and to CD3 on ...
... 7 Pharmatech Oncology, Inc., a Research Management Organization ... companies at the Company Showcase during BIOZONA 2009 - ... Downtown on April 7th in Phoenix, Arizona.Matthew B. Wiener, ... during the first session of the conference. The ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2
(Date:10/22/2014)... by Northwestern Medicine® scientists helps explain how bipolar disorder ... new drug therapies to treat the mental illness. ... the same method recognized with the 2014 Nobel ... brain tissue from mice with bipolar-like behaviors. In the ... tiny "nanodomain" structures with concentrated levels of ANK3 -- ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... million years ago, when the lineage of humans and ... turnips may have been one of the reasons. According ... of Minnesota and Richard Wrangham of Harvard University, the ... tubers must have sustained our ancestors who left the ...
... all likely to blame for poisoning the waters being drained from ... is leaving behind -- also owes its contamination to a source ... environments that made their way en masse into the water as ... Florida professor who has spent years studying the harmful contaminants that ...
... other non-terminal, debilitating conditions and diseases is both feasible ... such test on the approach in patients with advanced ... edition of the Proceedings of the National Academy of ... the potential to block the destructive inflammation process that ...
Cached Biology News:The roots of civilization trace back to ... roots 2Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 2Results of world's first gene therapy trial for arthritis show approach safe, feasible 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 4
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: